PMID- 37303932
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230613
IS  - 2220-3206 (Print)
IS  - 2220-3206 (Electronic)
IS  - 2220-3206 (Linking)
VI  - 13
IP  - 5
DP  - 2023 May 19
TI  - Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A 
      literature review.
PG  - 182-190
LID - 10.5498/wjp.v13.i5.182 [doi]
AB  - With the Food and Drug Administration designation in 2017 of 
      3,4-methylenedioxymethamphetamine (MDMA) as a breakthrough therapy in 
      post-traumatic stress disorder and psilocybin in treatment-resistant depression, 
      psychedelic drugs have continued to garner the attention of researchers and 
      clinicians for their promise of unmatched, rapid improvement in a multitude of 
      psychiatric conditions. Classic psychedelic drugs including psilocybin, lysergic 
      acid diethylamide, and ayahuasca, as well as non-classic drugs such as MDMA and 
      ketamine, are currently being investigated for a potential therapeutic role in 
      trauma, depressive disorders, and other psychopathologies. However, psilocybin 
      and MDMA each have a functional profile well-suited for integration with 
      psychotherapy. The present review focuses on psilocybin and MDMA in 
      psychedelic-assisted therapy (PAT), as these studies compose most of the 
      literature pool. In this review, we discuss the current and future uses of 
      psychedelic drugs, with an emphasis on the role of MDMA and psilocybin in PAT in 
      the setting of trauma and related comorbidities on the efficacy of psychedelic 
      drugs across multiple psychiatric disorders. The article concludes with thoughts 
      for future research, such as incorporating wearables and standardization of 
      symptom scales, therapy styles, and assessment of adverse drug reactions.
CI  - (c)The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Fonseka, Lakshan N
AU  - Fonseka LN
AD  - Harvard South Shore-Psychiatry Residency Program, Veteran Affairs Boston 
      Healthcare System, Brockton, MA 02301, United States.
FAU - Woo, Benjamin Kp
AU  - Woo BK
AD  - Chinese American Health Promotion Laboratory, University of California, Los 
      Angeles, Los Angeles, CA 90095, United States.
AD  - Department of Psychiatry and Biobehavioral Sciences, Olive View - University of 
      California, Los Angeles Medical Center, Sylmar, CA 91342, United States.
AD  - Asian American Studies Center, University of California, Los Angeles, Los 
      Angeles, CA 90095, United States.
AD  - Podiatric Medicine and Surgery, Western University of Health Sciences, Pomona, CA 
      91766, United States. bkpwoo@ucla.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230519
PL  - United States
TA  - World J Psychiatry
JT  - World journal of psychiatry
JID - 101610480
PMC - PMC10251361
OTO - NOTNLM
OT  - Depression
OT  - Ecstasy
OT  - Methylenedioxymethamphetamine
OT  - Psilocybin
OT  - Psychedelics
OT  - Trauma
COIS- Conflict-of-interest statement: All the authors report no relevant conflicts of 
      interest for this article.
EDAT- 2023/06/12 06:42
MHDA- 2023/06/12 06:43
PMCR- 2023/05/19
CRDT- 2023/06/12 04:00
PHST- 2023/01/19 00:00 [received]
PHST- 2023/02/28 00:00 [revised]
PHST- 2023/04/13 00:00 [accepted]
PHST- 2023/06/12 06:43 [medline]
PHST- 2023/06/12 06:42 [pubmed]
PHST- 2023/06/12 04:00 [entrez]
PHST- 2023/05/19 00:00 [pmc-release]
AID - 10.5498/wjp.v13.i5.182 [doi]
PST - epublish
SO  - World J Psychiatry. 2023 May 19;13(5):182-190. doi: 10.5498/wjp.v13.i5.182. 
      eCollection 2023 May 19.